Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb Tablet (Fimasartan) in Healthy Subjects
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Fimasartan (Primary) ; Fimasartan (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- 15 Mar 2015 Status changed from recruiting to completed according to an abstract published at the 116th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 28 Aug 2012 New trial record